The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | June 5 - 6, 2024

Biotech & Pharma Updates | June 5 - 6, 2024

Boehringer & Zealand Pharma Ph2 NASH data "unintentionally" published early, Seres Therapeutics sells a commercial asset to stay afloat, Abbvie's $10.1B ImmunoGen acquisition delivers Ph2 win, Nucleus RadioPharma fundraise, and Structure Therapeutics hopes to ride the data wave to a $476M stock sale

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | June 4 - 5, 2024

Biotech & Pharma Updates | June 4 - 5, 2024

Amgen's Ph3 rare disease success from $27.8B Horizon acquisition, Annexon sells $125M in common stock, Telix Pharmaceuticals plans $200M IPO, and Finland's taking no chances with bird flu.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | June 3 - 4, 2024

Biotech & Pharma Updates | June 3 - 4, 2024

Lykos gets an FDA advisory thumbs down, BridgeBio & Viking Therapeutics deliver positive results but their stocks drop anyway, AstraZeneca's "armoured" CAR-T, and Summit cashes in $200M from an institutional investor.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | June 1 - 3, 2024

Biotech & Pharma Updates | June 1 - 3, 2024

Eli Lilly buys an ALS asset, Caribou touts partial HLA matching for allogeneic cell therapies, Jazz has "unprecedented" long-term data, and Merck discusses a post-Keytruda future.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | May 30 - June 2, 2024

Biotech & Pharma Updates | May 30 - June 2, 2024

GSK's ADC comeback story, Sanofi & Regeneron receive mixed signals, Moderna gets RSV vaccine approval, and an MDMA treatment lands FDA scrutiny.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
📈📉 Biotech & Pharma Stock Market Recap | May 27 - 31, 2024

📈📉 Biotech & Pharma Stock Market Recap | May 27 - 31, 2024

🧬 Winners, Losers, and Upcoming Earnings Calls

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | May 29 - 30, 2024

Biotech & Pharma Updates | May 29 - 30, 2024

Merck gets beaten at it’s own game, BMS lands another CAR-T indication, Otsuka dives into digital therapeutics, and "hub-and-spoke" biotech raises $73M.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | May 28 - 29, 2024

Biotech & Pharma Updates | May 28 - 29, 2024

FDA approvals for Amgen and Tris Pharma, BMS' $80M global licensing spend, BioNTech continues Africa push with $145M, and Novo Nordisk blames the American Healthcare System

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | May 27 - 28, 2024

Biotech & Pharma Updates | May 27 - 28, 2024

Pfizer naps a Priority Review Voucher, 3 separate $1B+ acquisitions, Insmed stock doubles on Ph3 results, and Takeda begins restructuring with 600+ layoffs.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | May 23 - 27, 2024

Biotech & Pharma Updates | May 23 - 27, 2024

ASCO news up the wazoo, CAR-T attacks solid tumors, the first reported case of diabetes cured by cell therapy, and positive Ph1/2 data turns sour on safety profile.

Anis Fahandej-Sadi
Anis Fahandej-Sadi
📈📉 Biotech & Pharma Stock Market Recap | May 20 - 24, 2024

📈📉 Biotech & Pharma Stock Market Recap | May 20 - 24, 2024

🧬 Winners, Losers, and Upcoming Earnings Calls

Anis Fahandej-Sadi
Anis Fahandej-Sadi
Biotech & Pharma Updates | May 22 - 23, 2024

Biotech & Pharma Updates | May 22 - 23, 2024

Takeda's sticky $1.2B partnership, two new funds totally $350M+, Adderall no longer in short supply, two big pharmas ordered to pay Hawaii nearly $1B

Anis Fahandej-Sadi
Anis Fahandej-Sadi
FirstBack
6789101112
Next Last